Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice

@article{Elbarbry2017VancomycinDA,
  title={Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice},
  author={Fawzy A Elbarbry},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  year={2017},
  volume={43},
  pages={259-268}
}
  • F. Elbarbry
  • Published 2017
  • Medicine
  • European Journal of Drug Metabolism and Pharmacokinetics
After more than six decades of its use as the mainstay antibiotic for the treatment of multidrug-resistant Gram-positive bacterial infections, dosing and monitoring of vancomycin therapy have not been optimized. The current vancomycin therapeutic guidelines recommend empiric doses of 15–20 mg/kg administered by intermittent infusion every 8–12 h in patients with normal kidney function. Additionally, the guidelines recommend trough concentration of 15–20 mg/L as a therapeutic goal for adult… Expand
Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections
TLDR
Vancomycin troughs of <5mg/L at initial steady state were associated with significantly compromised clinical outcomes in terms of risk of therapy prolongation, retreatment, and aggressive dose up-titration, compared to >10 mg/L troughs in pediatric patients with GPB infections. Expand
PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support.
TLDR
Preliminary results suggest that therapeutic drug monitoring could optimise the achievement of pharmacokinetic objectives associated with an effective antibiotic therapy. Expand
Dose Optimization of Vancomycin Using a Mechanism-Based Exposure-Response Model in Pediatric Infectious Disease Patients.
TLDR
This study confirmed that the changes in bacterial counts and CRP levels were well described with mechanistic exposure-response modeling of vancomycin, and can be used to determine optimal empiric doses of van comycin and to improve therapeutic outcomes in pediatric patients with GPB. Expand
Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution
TLDR
The recommended maintenance dose for vancomycin in severe pneumonia patients was 400–650 mg every 12 h, which was calculated based on CL tot, to achieve a trough concentration of 15–20 mg/L at steady state. Expand
An AUC Target Simulation for Vancomycin in Patients With Class III Obesity
TLDR
A target AUC approach required less vancomycin over a 24-hour time period relative to a target trough approach, suggesting that therapeutic drug monitoring that explicitly targets AUC may reduce vancomYcin exposure and potentially decrease the risk of nephrotoxicity in patients with class III obesity. Expand
Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients.
TLDR
The developed population vancomycin model may be used in estimating individual CL for adult critically ill septic patients, and could be applied for individualizing dosage regimens taking into account the continuous effect of CrCl. Expand
Effect of N-acetylcysteine against Vancomycin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial.
TLDR
N-acetylcysteine (NAC), an anti-oxidant agent, has the potential for reduction of VIN, however, more studies are necessary to confirm this effect. Expand
Factors increasing the risk of inappropriate vancomycin therapy in ICU patients: A prospective observational study
TLDR
Patients at risk of therapeutic failure defined as vancomycin area‐under‐the‐curve0‐24/minimum inhibitory concentration (AUC0-24/MIC) <400 are identified to examine possible effects of different MICs, the variability in renal clearance and continuous renal replacement therapy (CRRT), and the relevance of vancomYcin therapy. Expand
Correlates and Outcomes of Early Acute Kidney Injury after Hematopoietic Cell Transplantation.
TLDR
AKI is a frequent complication following HCT and is associated with a higher risk of ICU transfer and higher mortality post HCT, while a higher vancomycin trough level may be indicative of a higherrisk of AKI, the risk following CNI exposure may not related to trough levels alone. Expand
Vancomycin and creatinine determination in dried blood spots: Analytical validation and clinical assessment.
TLDR
A liquid chromatography tandem-mass spectrometry method for vancomycin and creatinine measurement in dried blood spots (DBS) and to evaluate its clinical application has adequate analytical performance. Expand
...
1
2
...

References

SHOWING 1-10 OF 45 REFERENCES
Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
TLDR
Stable serum levels at the expected target were obtained at the population level, but large intrapatient variations required frequent dose re-adjustments, and Recursive partitioning analysis of AUC/MIC ratios versus success or failure suggested threshold values of 667 and 451, corresponding to organisms with a MIC>1 mg/L. Expand
Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients
TLDR
These nomograms could be helpful in improving the vancomycin treatment of MRSA infections, especially in the presence of borderline-susceptible pathogens and/or of pathophysiological conditions which may enhance the clearance of vancomYcin, while potentially avoiding the increased risk of nephrotoxicity observed with the use of high intermittent doses of van comycin. Expand
Outcome Assessment of Minimizing Vancomycin Monitoring and Dosing Adjustments
An approach to minimize monitoring of vancomycin therapy was evaluated in 120 patients, and results were compared with data from 120 patients in whom vancomycin therapy was monitored and adjustedExpand
Optimizing the Clinical Use of Vancomycin
TLDR
This review analyzes the new available information about vancomycin published in recent years regarding pharmacokinetics and pharmacodynamics, serum concentration monitoring, and optimal vancomYcin dosing in special situations (obese people, burn patients, renal replacement therapy, among others). Expand
Innovative approaches to optimizing the delivery of vancomycin in individual patients.
TLDR
Two innovative approaches for calculating the vancomycin AUC in clinical practice based on one or two drug concentrations are reviewed, one of which involves the use of Bayesian computer software programs to estimate the "true" AUC value with minimal PK sampling and provide AUC-guided dosing recommendations at the bedside. Expand
Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections
TLDR
It is concluded that CI and CD vancomycin therapy demonstrated equivalent pharmacodynamic activities and CI administration of vancomYcin should be further evaluated to determine the clinical utility of this method of administration. Expand
AUC Versus Peak–Trough Dosing of Vancomycin: Applying New Pharmacokinetic Paradigms to an Old Drug
TLDR
An understanding of pharmacokinetic and pharmacodynamic principles, including the relevance of AUC in relation to MIC, enables clinicians to make the best use of vancomycin dosing options. Expand
Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study
TLDR
For comparable efficacy and tolerance, CIV may be a cost-effective alternative to IIV in severe hospital-acquired methicillin-resistant staphylococcal infections. Expand
Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections.
TLDR
No difference in rates of clinical failure of continuous infusion and intermittent infusion of vancomycin was observed in this outpatient cohort, and logistic regression to adjust for differences in age, co-morbidity, subtherapeutic levels and prosthetic devices did not substantially alter this result. Expand
Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy.
TLDR
In adult OPAT patients with normal renal function, vancomycin CI was associated with a slower onset of nephrotoxicity but not a lower prevalence of neephrotoxicity, both in unadjusted and adjusted analyses. Expand
...
1
2
3
4
5
...